Merck to Pay at Least $70 Million for Rights to Abbisko Joint-Tumor Drug
By David Sachs
Merck has a deal worth at least $70 million with Abbisko Therapeutics to commercialize a drug to treat joint tumors.
The German pharmaceutical company said Monday that its deal with the Chinese drugmaker allows the company to commercialize pimicotinib, a phase-3 pill that treats tenosynovial giant cell tumor. Merck said it will pay $70 million up front for the exclusive rights, with additional payments for meeting certain regulatory and commercial milestones. Merck also has the option to co-develop the drug for a fee, it said.
The deal applies to mainland China, Hong Kong, Macau and Taiwan, with an option for the rest of the world. Regulators in China and the U.S. have deemed the medicine a breakthrough while European regulators have designated it a priority drug, Merck said.
"Pimicotinib provides an opportunity to address a significant unmet medical need and for us to expand our commercial footprint in oncology in China, the second largest pharmaceutical market in the world," said Andrew Paterson, chief marketing officer for Merck's healthcare arm.
Write to David Sachs at david.sachs@wsj.com
-0-
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
December 04, 2023 08:54 ET (13:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing